Back to news

PRISM MarketView Highlights Four Small Caps Working on Alzheimer’s Disease for National Alzheimer’s Disease Awareness Month

Globe Newswire•19/11/2026•12:08 ET
0

Key Highlights

  • ➤Biogen’s diranersen lowest dose slowed decline 38% at two years
  • ➤Priavoid’s PRI-002 missed its efficacy endpoint
  • ➤Lilly is ending development of mevidalen
  • ➤Annovis Bio expects Phase 3 buntanetap results in March 2027
  • ➤AC Immune’s ACI-24 produced antibody responses without ARIA-E in 74 patients

NEW YORK, Nov. 19, 2026 (GLOBE NEWSWIRE) -- PRISM MarketView, a financial media platform covering small-cap public companies through 27 thematic indexes, today published a National Alzheimer’s Disease Awareness Month feature on four small-cap companies working on Alzheimer’s disease, from treatment to testing.

The feature follows this week’s Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston, where readouts pointed in different directions. Biogen reported that the lowest dose of diranersen slowed decline by 38% at two years in an open-label extension, while Priavoid’s PRI-002 missed its efficacy endpoint and Lilly is ending development of mevidalen.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in